Solid Biosciences Inc.: peers
Solid Biosciences Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Solid Biosciences Inc.base SLDB · 🇺🇸 US Percentile in Healthcare Percentile in USA | Collegium Pharmaceutical, Inc. COLL · 🇺🇸 US Percentile in Healthcare Percentile in USA | Ironwood Pharmaceuticals, Inc. IRWD · 🇺🇸 US Percentile in Healthcare Percentile in USA | Aquestive Therapeutics, Inc. AQST · 🇺🇸 US Percentile in Healthcare Percentile in USA | Evolus, Inc. EOLS · 🇺🇸 US Percentile in Healthcare Percentile in USA | Alpha Teknova, Inc. TKNO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Harrow Health HROW · 🇺🇸 US Percentile in Healthcare Percentile in USA | Amphastar Pharmaceuticals, Inc. AMPH · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $713 MOct 30, 2026 · Market data4th of 8 | $715 MOct 28, 2026 · Market data3rd of 8 | $599 MOct 30, 2026 · Market data5th of 8 | $508 MOct 30, 2026 · Market data6th of 8 | $501 MOct 16, 2026 · Market data7th of 8 | $494 MOct 29, 2026 · Market data8th of 8 | $1.1 BOct 28, 2026 · Market data1st of 8 | $1.1 BOct 28, 2026 · Market data2nd of 8 | $656 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $781 MFY2025 · SEC1st of 7 | $296 MFY2025 · SEC4th of 7 | $45 MFY2025 · SEC6th of 7 | $297 MFY2025 · SEC3rd of 7 | $41 MFY2025 · SEC7th of 7 | $272 MFY2025 · SEC5th of 7 | $720 MFY2025 · SEC2nd of 7 | $296 M7 ranked |
| Net income (Higher is better) | $-174 MFY2025 · SEC8th of 8 | $63 MFY2025 · SEC2nd of 8 | $24 MFY2025 · SEC3rd of 8 | $-84 MFY2025 · SEC7th of 8 | $-52 MFY2025 · SEC6th of 8 | $-17 MFY2025 · SEC5th of 8 | $-5 MFY2025 · SEC4th of 8 | $98 MFY2025 · SEC1st of 8 | $-11 M8 ranked |
| Employees (Better neither way: ranked highest first) | —— | 234As on December 2020 · Profile3rd of 6 | 219As on 2021 · Profile4th of 6 | 147December 31, 2025 · Profile6th of 6 | 334December 31, 2025 · Profile2nd of 6 | 158December 31, 2025 · Profile5th of 6 | —— | 1,761As on 2021 · Profile1st of 6 | 2276 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | +23.6%FY2025 · SEC2nd of 773rd82nd | -15.7%FY2025 · SEC6th of 712th7th | -22.6%FY2025 · SEC7th of 710th5th | +11.6%FY2025 · SEC3rd of 753rd65th | +7.4%FY2025 · SEC4th of 743rd53rd | +36.4%FY2025 · SEC1st of 780th88th | -1.6%FY2025 · SEC5th of 722nd25th | +7.4%7 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | +18.9%FY2025 · SEC3rd of 771st84th | -10.3%FY2025 · SEC7th of 712th10th | -2.3%FY2025 · SEC6th of 721st25th | +26.0%FY2025 · SEC2nd of 778th89th | -0.7%FY2025 · SEC5th of 725th30th | +45.4%FY2025 · SEC1st of 787th95th | +13.0%FY2025 · SEC4th of 761st76th | +13.0%7 ranked |
| Earnings per share growth (Higher is better) | ———— | -7.0%FY2025 · SEC1st of 230th31st | ———— | ———— | ———— | ———— | ———— | -33.7%FY2025 · SEC2nd of 215th15th | -20.3%2 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | 59.4%FY2025 · SEC3rd of 652nd73rd | ———— | 58.3%FY2025 · SEC4th of 650th72nd | 66.3%FY2025 · SEC2nd of 662nd79th | 33.2%FY2025 · SEC6th of 619th40th | 75.0%FY2025 · SEC1st of 675th87th | 49.5%FY2025 · SEC5th of 635th63rd | 58.8%6 ranked |
| Operating margin (Higher is better) | ———— | 23.0%FY2025 · SEC2nd of 791st89th | 33.3%FY2025 · SEC1st of 796th95th | -159.5%FY2025 · SEC7th of 717th7th | -11.0%FY2025 · SEC5th of 747th26th | -41.9%FY2025 · SEC6th of 734th16th | 11.2%FY2025 · SEC4th of 775th71st | 19.5%FY2025 · SEC3rd of 788th85th | 11.2%7 ranked |
| Net margin (Higher is better) | ———— | 8.1%FY2025 · SEC3rd of 775th70th | 8.1%FY2025 · SEC2nd of 775th70th | -188.1%FY2025 · SEC7th of 716th6th | -17.4%FY2025 · SEC5th of 744th23rd | -42.6%FY2025 · SEC6th of 732nd16th | -1.9%FY2025 · SEC4th of 757th39th | 13.6%FY2025 · SEC1st of 784th82nd | -1.9%7 ranked |
| Free cash flow margin (Higher is better) | ———— | 42.0%FY2025 · SEC2nd of 798th98th | 42.9%FY2025 · SEC1st of 798th99th | -119.0%FY2025 · SEC7th of 719th7th | -15.4%FY2025 · SEC5th of 739th18th | -24.2%FY2025 · SEC6th of 735th16th | 15.8%FY2025 · SEC4th of 782nd82nd | 16.8%FY2025 · SEC3rd of 783rd83rd | 15.8%7 ranked |
| Return on equity (Higher is better) | -109.9%FY2025 · SEC5th of 522nd10th | 23.7%FY2025 · SEC1st of 593rd88th | ———— | ———— | ———— | -22.8%FY2025 · SEC4th of 559th27th | -8.4%FY2025 · SEC3rd of 567th34th | 12.9%FY2025 · SEC2nd of 585th73rd | -8.4%5 ranked |
| Return on invested capital (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | 9.2%FY2025 · SEConly one with it37th42nd | 9.2%— |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | 18.7×price Oct 28, 2026 · Market data1st of 329th49th | 4.0×price Oct 30, 2026 · Market data3rd of 35th3rd | ———— | ———— | ———— | ———— | 11.0×price Oct 28, 2026 · Market data2nd of 314th21st | 11.0×3 ranked |
| Price to sales (Better neither way: ranked highest first) | ———— | 0.9×price Oct 28, 2026 · Market data7th of 715th26th | 1.5×price Oct 30, 2026 · Market data5th of 724th40th | 10.4×price Oct 30, 2026 · Market data2nd of 774th89th | 1.5×price Oct 16, 2026 · Market data4th of 725th40th | 10.8×price Oct 29, 2026 · Market data1st of 775th90th | 3.6×price Oct 28, 2026 · Market data3rd of 749th68th | 1.5×price Oct 28, 2026 · Market data6th of 723rd39th | 1.5×7 ranked |
| Price to book (Better neither way: ranked highest first) | 4.0×price Oct 30, 2026 · Market data3rd of 560th70th | 2.4×price Oct 28, 2026 · Market data4th of 542nd53rd | ———— | ———— | ———— | 7.2×price Oct 29, 2026 · Market data2nd of 577th84th | 20.8×price Oct 28, 2026 · Market data1st of 592nd96th | 1.4×price Oct 28, 2026 · Market data5th of 526th33rd | 4.0×5 ranked |
| Free cash flow yield (Higher is better) | -22.1%price Oct 30, 2026 · Market data8th of 831st14th | 45.8%price Oct 28, 2026 · Market data1st of 899th99th | 21.2%price Oct 30, 2026 · Market data2nd of 898th96th | -10.4%price Oct 30, 2026 · Market data7th of 842nd20th | -9.1%price Oct 16, 2026 · Market data6th of 844th22nd | -2.0%price Oct 29, 2026 · Market data5th of 862nd32nd | 3.9%price Oct 28, 2026 · Market data4th of 883rd59th | 11.1%price Oct 28, 2026 · Market data3rd of 895th89th | 1.0%8 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | ———— | ———— | 0.2×FY2025 · SEC1st of 331st22nd | 4.8×FY2025 · SEC3rd of 394th94th | 0.8×FY2025 · SEC2nd of 369th60th | 0.8×3 ranked |
| Net debt to EBITDA (Lower is better) | ———— | ———— | ———— | ———— | ———— | ———— | 5.5×FY2025 · SEConly one with it86th84th | ———— | 5.5×— |
| Piotroski F-score (Higher is better) | —— | —— | —— | 2 of 9FY2025 · SEC4th of 5 | 2 of 9FY2025 · SEC4th of 5 | 5 of 9FY2025 · SEC3rd of 5 | 6 of 9FY2025 · SEC1st of 5 | 6 of 9FY2025 · SEC1st of 5 | 5.0 of 95 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 1 of 12FY2025 · Scorecard8th of 8 | 20 of 23FY2025 · Scorecard1st of 8 | 11 of 20FY2025 · Scorecard3rd of 8 | 2 of 20FY2025 · Scorecard7th of 8 | 8 of 19FY2025 · Scorecard4th of 8 | 6 of 21FY2025 · Scorecard6th of 8 | 9 of 23FY2025 · Scorecard5th of 8 | 20 of 25FY2025 · Scorecard2nd of 8 | 41% passed8 ranked |
| Valuation checks (Higher is better) | 0 of 4FY2025 · Scorecard6th of 8 | 6 of 6FY2025 · Scorecard1st of 8 | 5 of 6FY2025 · Scorecard3rd of 8 | 0 of 5FY2025 · Scorecard6th of 8 | 1 of 5FY2025 · Scorecard4th of 8 | 0 of 5FY2025 · Scorecard6th of 8 | 1 of 6FY2025 · Scorecard5th of 8 | 6 of 6FY2025 · Scorecard1st of 8 | 18% passed8 ranked |
| Growth checks (Higher is better) | 0 of 2FY2025 · Scorecard7th of 8 | 5 of 6FY2025 · Scorecard1st of 8 | 1 of 6FY2025 · Scorecard6th of 8 | 0 of 6FY2025 · Scorecard7th of 8 | 5 of 6FY2025 · Scorecard1st of 8 | 2 of 6FY2025 · Scorecard5th of 8 | 4 of 6FY2025 · Scorecard3rd of 8 | 4 of 6FY2025 · Scorecard3rd of 8 | 50% passed8 ranked |
| Profitability checks (Higher is better) | 0 of 3FY2025 · Scorecard7th of 8 | 4 of 5FY2025 · Scorecard1st of 8 | 2 of 4FY2025 · Scorecard2nd of 8 | 0 of 4FY2025 · Scorecard7th of 8 | 1 of 4FY2025 · Scorecard5th of 8 | 1 of 5FY2025 · Scorecard6th of 8 | 2 of 5FY2025 · Scorecard4th of 8 | 3 of 6FY2025 · Scorecard2nd of 8 | 33% passed8 ranked |
| Financial health checks (Higher is better) | 1 of 2FY2025 · Scorecard5th of 8 | 2 of 3FY2025 · Scorecard3rd of 8 | 2 of 3FY2025 · Scorecard3rd of 8 | 2 of 4FY2025 · Scorecard5th of 8 | 1 of 3FY2025 · Scorecard8th of 8 | 3 of 4FY2025 · Scorecard2nd of 8 | 2 of 5FY2025 · Scorecard7th of 8 | 4 of 4FY2025 · Scorecard1st of 8 | 58% passed8 ranked |
| Shareholder returns checks (Higher is better) | 0 of 1FY2025 · Scorecard4th of 8 | 3 of 3FY2025 · Scorecard1st of 8 | 1 of 1FY2025 · Scorecard1st of 8 | 0 of 1FY2025 · Scorecard4th of 8 | 0 of 1FY2025 · Scorecard4th of 8 | 0 of 1FY2025 · Scorecard4th of 8 | 0 of 1FY2025 · Scorecard4th of 8 | 3 of 3FY2025 · Scorecard1st of 8 | 0% passed8 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 106.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 118.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 92.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 60.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 76.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 16.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 60.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 68.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 72.5%8 ranked |
| Institutions holding (Better neither way: ranked highest first) | 1582026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 2402026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 2322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 1902026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 1702026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 1102026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 2082026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 2272026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 1998 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | +5.3 pp2026-Q2 against 2026-Q1 · 13F2nd of 8 | +5.0 pp2026-Q2 against 2026-Q1 · 13F3rd of 8 | -0.2 pp2026-Q2 against 2026-Q1 · 13F6th of 8 | -1.4 pp2026-Q2 against 2026-Q1 · 13F7th of 8 | +14.6 pp2026-Q2 against 2026-Q1 · 13F1st of 8 | +2.7 pp2026-Q2 against 2026-Q1 · 13F4th of 8 | -0.1 pp2026-Q2 against 2026-Q1 · 13F5th of 8 | -6.2 pp2026-Q2 against 2026-Q1 · 13F8th of 8 | +1.3 pp8 ranked |
| Dividends | |||||||||
| Shareholder yield (Higher is better) | ———— | 3.5%FY2025 · SEC2nd of 263rd54th | ———— | ———— | ———— | ———— | ———— | 6.9%FY2025 · SEC1st of 284th79th | 5.2%2 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Solid Biosciences Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Collegium Pharmaceutical, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Ironwood Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Aquestive Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Evolus, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Alpha Teknova, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Harrow Health: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Amphastar Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Solid Biosciences Inc. | — | — | — |
| Collegium Pharmaceutical, Inc. | 23.0%FY2025 | 91st percentile in Healthcaremedian -7.7%, 674 companies | 89th percentile in USAmedian 3.5%, 2,594 companies |
| Ironwood Pharmaceuticals, Inc. | 33.3%FY2025 | 96th percentile in Healthcaremedian -7.7%, 674 companies | 95th percentile in USAmedian 3.5%, 2,594 companies |
| Aquestive Therapeutics, Inc. | -159.5%FY2025 | 17th percentile in Healthcaremedian -7.7%, 674 companies | 7th percentile in USAmedian 3.5%, 2,594 companies |
| Evolus, Inc. | -11.0%FY2025 | 47th percentile in Healthcaremedian -7.7%, 674 companies | 26th percentile in USAmedian 3.5%, 2,594 companies |
| Alpha Teknova, Inc. | -41.9%FY2025 | 34th percentile in Healthcaremedian -7.7%, 674 companies | 16th percentile in USAmedian 3.5%, 2,594 companies |
| Harrow Health | 11.2%FY2025 | 75th percentile in Healthcaremedian -7.7%, 674 companies | 71st percentile in USAmedian 3.5%, 2,594 companies |
| Amphastar Pharmaceuticals, Inc. | 19.5%FY2025 | 88th percentile in Healthcaremedian -7.7%, 674 companies | 85th percentile in USAmedian 3.5%, 2,594 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Solid Biosciences Inc. | Collegium Pharmaceutical, Inc. | Ironwood Pharmaceuticals, Inc. | Aquestive Therapeutics, Inc. | Evolus, Inc. | Alpha Teknova, Inc. | Harrow Health | Amphastar Pharmaceuticals, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | $781 MSEC1st | $296 MSEC4th | $45 MSEC6th | $297 MSEC3rd | $41 MSEC7th | $272 MSEC5th | $720 MSEC2nd |
| 2024 | — | $631 MSEC2nd | $351 MSEC3rd | $58 MSEC6th | $266 MSEC4th | $38 MSEC7th | $200 MSEC5th | $732 MSEC1st |
| 2023 | — | $567 MSEC2nd | $443 MSEC3rd | $51 MSEC6th | $202 MSEC4th | $37 MSEC7th | $130 MSEC5th | $644 MSEC1st |
| 2022 | $8 MSEC8th | $464 MSEC2nd | $411 MSEC3rd | $48 MSEC6th | $149 MSEC4th | $41 MSEC7th | $89 MSEC5th | $499 MSEC1st |
| 2021 | $14 MSEC8th | $277 MSEC3rd | $414 MSEC2nd | $51 MSEC6th | $100 MSEC4th | $37 MSEC7th | $72 MSEC5th | $438 MSEC1st |
| 2020 | — | $310 MSEC3rd | $390 MSEC1st | $46 MSEC6th | $57 MSEC4th | $31 MSEC7th | $49 MSEC5th | $350 MSEC2nd |
| 2019 | — | $297 MSEC3rd | $428 MSEC1st | $53 MSEC4th | $35 MSEC6th | — | $51 MSEC5th | $322 MSEC2nd |
| 2018 | — | $280 MSEC3rd | $347 MSEC1st | $67 MSEC4th | — | — | $41 MSEC5th | $295 MSEC2nd |
| 2017 | — | $28 MSEC4th | $298 MSEC1st | $67 MSEC3rd | — | — | $27 MSEC5th | $240 MSEC2nd |
| 2016 | — | $2 MSEC4th | $274 MSEC1st | — | — | — | $20 MSEC3rd | $255 MSEC2nd |
| 2015 | — | — | $150 MSEC2nd | — | — | — | $10 MSEC3rd | $252 MSEC1st |
| 2014 | — | — | $76 MSEC2nd | — | — | — | $2 MSEC3rd | $210 MSEC1st |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Solid Biosciences Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Collegium Pharmaceutical, Inc.COLL · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $715 M market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $715 M (Oct 28, 2026) · revenue $781 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Ironwood Pharmaceuticals, Inc.IRWD · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $599 M market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $599 M (Oct 30, 2026) · revenue $296 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Aquestive Therapeutics, Inc.AQST · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $508 M market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $508 M (Oct 30, 2026) · revenue $45 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Evolus, Inc.EOLS · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $501 M market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $501 M (Oct 16, 2026) · revenue $297 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Alpha Teknova, Inc.TKNO · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $494 M market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $494 M (Oct 29, 2026) · revenue $41 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Harrow HealthHROW · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $1.1 B market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $1.1 B (Oct 28, 2026) · revenue $272 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- Amphastar Pharmaceuticals, Inc.AMPH · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $1.1 B market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $1.1 B (Oct 28, 2026) · revenue $720 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- Emergent BioSolutions Inc.EBS · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $365 M market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $365 M (Oct 29, 2026) · revenue $743 M (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)+ Add
- Pacira BioSciences, Inc.PCRX · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $1.5 B market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $1.5 B (Oct 29, 2026) · revenue $726 M (year to December 2025)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)+ Add
- Phibro Animal Health CorporationPAHC · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $1.6 B market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $1.6 B (Oct 30, 2026) · revenue $1.5 B (year to June 2026)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)+ Add
- ANI Pharmaceuticals, Inc.ANIP · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $1.6 B market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $1.6 B (Oct 9, 2026) · revenue $883 M (year to December 2025)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)+ Add
- Bayport International Holdings Inc.BAYP · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $820 M market cap against $713 M · Same country: USAMarket cap $820 M (last known, Jan 7, 2022)94 of 100 (industry or sector 50 + size 29 + country 15)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.